Developer docs
API playgroundTry for free, no card

Search company profiles

SweetBio

Full company profile

uuid0000cbd

Namestring
SweetBio
Legal namestring
SweetBio Inc.
Websiteurl
sweetbio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

SweetBio is a privately-held medical device company founded in 2015 and headquartered at the University of Memphis CommuniTech Research Park. The company develops and commercializes bioengineered wound care products built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite — protected by granted patent and supported by 15 years of foundational tissue engineering research by co-founder and CSO Dr. Isaac Rodriguez. SweetBio sells two FDA-cleared, Medicare-covered products: VERIS, a daily collagen dressing reimbursed under HCPCS A6021 for routine clinic wounds, and APIS, a weekly cellular and/or tissue-based product (CTP/skin substitute) reimbursed under HCPCS A2010 for chronic and acute wounds. Clinical evidence includes a 37-patient Mohs RCT at Vanderbilt, a 12-patient chronic wound case series showing 100% closure within 8 weeks, and a 43-patient urban hospital study demonstrating 2x faster closure versus standard of care.

The company operates a hybrid sales-and-distribution model, selling directly to healthcare providers — including wound care clinics, dermatology departments, and integrated health systems — while leveraging national distribution partners BioLab Holdings and Resolve Medical for channel scale. APIS is now available across all Medicare Administrative Contractors (MACs) and in Veterans Affairs and Department of Defense facilities. SweetBio has raised approximately $4.55 million across multiple rounds led primarily by Innova Memphis with participation from MB Venture Partners, The JumpFund, ZeroTo510, and VamosVentures, plus a 2021 grant from Apple's Racial Equity and Justice Initiative. The company has a 1–10 person team and is led by co-founder and CEO Kayla Rodriguez Graff alongside co-founder and CSO Isaac Rodriguez, PhD, and co-founder/CFO Kevin Graff.

Revenue model is unit-based hardware sales of wound care dressings reimbursed by Medicare and commercial payers. Forward growth depends on conversion of the two newly signed national distribution partnerships and continued clinical adoption across wound care, dermatology, and government health system channels.

Short descriptiontext

SweetBio is a Memphis-based medical device company that develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings (APIS and VERIS) combining Mānuka honey, collagen, and hydroxyapatite for chronic and acute wound treatment in clinical, dermatology, and VA/DOD settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMemphis, United States
HQ citystring
Memphis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wound care dressings, medical device manufacturing, regenerative wound healing, bioengineered skin substitute, advanced wound care products
Industry5 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKACAN
Wound Care & Ulcer Management
SECONDARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Wound Care Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of APIS and VERIS wound care products to healthcare providers, clinics, and hospital systems. Revenue generated through product sales with Medicare and commercial insurance reimbursement.

sweetbio.com
2Distribution Partnership Revenue
TypeHardware Sales
Description

Revenue through distribution partners BioLab Holdings and Resolve Medical who distribute SweetBio products through their national networks to healthcare providers.

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Pricing details2 tiers
1VERIS - Daily wound dressings
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Reimbursed by Medicare and most commercial plans as a low-cost wound supply (HCPCS A6021, collagen).

sweetbio.com
2APIS - Weekly CTP/skin substitute
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Billed under HCPCS code A2010, APIS. Now available across MACs and in Veterans Affairs and DOD facilities.

sweetbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1APIS®
Description

Weekly CTP / skin substitute supporting both chronic and acute wounds. The first wound care product combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. FDA-cleared and Medicare-covered.

sweetbio.com
+1 more record
Core offering1 text field

SweetBio develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company sells two SKUs — VERIS, a daily collagen dressing reimbursed under HCPCS A6021, and APIS, a weekly cellular tissue product/skin substitute reimbursed under HCPCS A2010 — to wound care clinics, dermatology departments, and hospital systems through national distribution partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% wound closure within 8 weeks (mean 4.1 weeks) in 12-patient chronic wound case series
+4 more records
Product overview1 text field

SweetBio® develops bioengineered wound care products using a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company offers two products: VERIS™ (daily collagen dressings for routine wound care, HCPCS A6021) and APIS® (weekly skin substitute/CTP for chronic and acute wounds, HCPCS A2010). Both products are FDA-cleared, Medicare-covered, and clinically proven to reduce time to wound closure compared to standard of care.

Product and service2 records
1VERIS™
CategoryWound Care Dressings
Description

VERIS is a daily wound dressing combining collagen and Mānuka honey for routine use in clinic settings. It is FDA-cleared, reimbursed by Medicare and most commercial plans as a low-cost wound supply (HCPCS A6021, collagen), and designed for healthcare providers treating common wounds seen every day in clinic.

2APIS®
CategorySkin Substitutes / Cellular Tissue Products
Description

APIS is a weekly cellular tissue product (CTP) / skin substitute combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite for the treatment of chronic and acute wounds. It is FDA-cleared, non-human (no placental, umbilical, or other human tissue), Medicare-covered under HCPCS A2010, and available across MACs and in Veterans Affairs and Department of Defense facilities.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-27
Description

Strategic distribution partnership to expand access to SweetBio's APIS bioengineered wound care products through BioLab's national distribution network. Expected to accelerate adoption among clinicians across care settings while strengthening BioLab's continuum-of-care portfolio.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-25
Description

Commercial launch partnership for APIS through Resolve Medical's established network of healthcare providers across the United States. Resolve Medical leads product distribution and launch activities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Resolve Medical
TypeEmerging player
Description

Specialty distributor focused on bringing advanced wound care products to US healthcare providers; leads APIS® commercial launch. Comparable as a channel peer and emerging commercialization partner in the advanced wound care category.

TypeBroad incumbent
Description

Major advanced wound care incumbent offering foam, hydrocolloid, antimicrobial, and biologic wound dressings. Overlaps with SweetBio on collagen and antimicrobial wound dressings (similar HCPCS A-codes) but operates at significantly broader global scale.

3Medline Industries
TypeBroad incumbent
Description

Largest privately-held manufacturer and distributor of medical supplies, including a broad wound care portfolio. Comparable as both a competing supplier and a channel partner option for SweetBio's hospital and clinic customers.

TypeBroad incumbent
Description

Owns the KCI negative pressure wound therapy franchise plus a range of advanced wound dressings. Comparable as a large channel competitor in advanced wound care, especially for hospital systems where SweetBio sells through BioLab and Resolve Medical.

TypeEmerging player
Description

Wound care distributor that recently added SweetBio's APIS® to its national portfolio. Comparable as a strategic channel peer whose continuum-of-care portfolio increasingly competes with and complements bioengineered skin substitute offerings.

TypeDirect peer
Description

Develops and markets placental tissue allografts used as skin substitutes and wound coverings. Directly comparable to SweetBio in product category (skin substitute/CCTPs), reimbursement dynamics under HCPCS Q-codes/A-codes, and target customer (wound care clinics, dermatologists, VA/DOD).

TypeBroad incumbent
Description

Global medical device incumbent with a large Advanced Wound Management portfolio (collagen dressings, honey-based dressings, skin substitutes via the Osiris acquisition). Comparable in product overlap (collagen/honey wound dressings, CTP/skin substitutes) though operating at much greater scale across multiple categories.

TypeDirect peer
Description

A leading regenerative medicine company commercializing skin substitutes and wound care biologics (e.g., Apligraf, Dermagraft). Directly comparable to SweetBio as both sell FDA-cleared, Medicare-covered skin substitutes/CTPs into the chronic and acute wound care market under similar HCPCS reimbursement pathways.

TypeBroad incumbent
Description

Global wound and skin care company with extensive advanced wound dressings portfolio. Overlaps with SweetBio on collagen-based and antimicrobial wound dressings sold into similar healthcare provider and outpatient settings.

TypeBroad incumbent
Description

Diversified regenerative medicine company with skin substitutes (e.g., Integra Dermal Regeneration Template) and wound care products. Comparable on regenerative skin substitute technology and Medicare-reimbursed wound care sales channels.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SweetBio

Wound Care Medical Devicessweetbio.com

SweetBio is a Memphis-based medical device company that develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings (APIS and VERIS) combining Mānuka honey, collagen, and hydroxyapatite for chronic and acute wound treatment in clinical, dermatology, and VA/DOD settings.

What SweetBio does

SweetBio is a privately-held medical device company founded in 2015 and headquartered at the University of Memphis CommuniTech Research Park. The company develops and commercializes bioengineered wound care products built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite — protected by granted patent and supported by 15 years of foundational tissue engineering research by co-founder and CSO Dr. Isaac Rodriguez. SweetBio sells two FDA-cleared, Medicare-covered products: VERIS, a daily collagen dressing reimbursed under HCPCS A6021 for routine clinic wounds, and APIS, a weekly cellular and/or tissue-based product (CTP/skin substitute) reimbursed under HCPCS A2010 for chronic and acute wounds. Clinical evidence includes a 37-patient Mohs RCT at Vanderbilt, a 12-patient chronic wound case series showing 100% closure within 8 weeks, and a 43-patient urban hospital study demonstrating 2x faster closure versus standard of care.

The company operates a hybrid sales-and-distribution model, selling directly to healthcare providers — including wound care clinics, dermatology departments, and integrated health systems — while leveraging national distribution partners BioLab Holdings and Resolve Medical for channel scale. APIS is now available across all Medicare Administrative Contractors (MACs) and in Veterans Affairs and Department of Defense facilities. SweetBio has raised approximately $4.55 million across multiple rounds led primarily by Innova Memphis with participation from MB Venture Partners, The JumpFund, ZeroTo510, and VamosVentures, plus a 2021 grant from Apple's Racial Equity and Justice Initiative. The company has a 1–10 person team and is led by co-founder and CEO Kayla Rodriguez Graff alongside co-founder and CSO Isaac Rodriguez, PhD, and co-founder/CFO Kevin Graff.

Revenue model is unit-based hardware sales of wound care dressings reimbursed by Medicare and commercial payers. Forward growth depends on conversion of the two newly signed national distribution partnerships and continued clinical adoption across wound care, dermatology, and government health system channels.

SweetBio firmographics

Firmographics
Name
SweetBio
Legal name
SweetBio Inc.
Website
https://sweetbio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
SweetBio is a Memphis-based medical device company that develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings (APIS and VERIS) combining Mānuka honey, collagen, and hydroxyapatite for chronic and acute wound treatment in clinical, dermatology, and VA/DOD settings.
Ownership category
akta.pro rank

SweetBio industry classification

Industry
Product category
Wound Care Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKACAN
Wound Care & Ulcer Management
SECONDARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Wound care dressings
  • Medical device manufacturing
  • Regenerative wound healing
  • Bioengineered skin substitute
  • Advanced wound care products

Where SweetBio is headquartered

Location

Headquarters

HQ city
Memphis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SweetBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Sale of APIS and VERIS wound care products to healthcare providers, clinics, and hospital systems. Revenue generated through product sales with Medicare and commercial insurance reimbursement.
  2. Distribution Partnership Revenue: Revenue through distribution partners BioLab Holdings and Resolve Medical who distribute SweetBio products through their national networks to healthcare providers.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goVERIS - Daily wound dressings
Unit PricingPay-as-you-goAPIS - Weekly CTP/skin substitute

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

SweetBio product offering

Product offering

Core offering

SweetBio develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company sells two SKUs — VERIS, a daily collagen dressing reimbursed under HCPCS A6021, and APIS, a weekly cellular tissue product/skin substitute reimbursed under HCPCS A2010 — to wound care clinics, dermatology departments, and hospital systems through national distribution partners.

Product overview

SweetBio® develops bioengineered wound care products using a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company offers two products: VERIS™ (daily collagen dressings for routine wound care, HCPCS A6021) and APIS® (weekly skin substitute/CTP for chronic and acute wounds, HCPCS A2010). Both products are FDA-cleared, Medicare-covered, and clinically proven to reduce time to wound closure compared to standard of care.

Differentiator

Problem solved

Functional benefit

Brands

  • APIS®: Weekly CTP / skin substitute supporting both chronic and acute wounds. The first wound care product combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. FDA-cleared and Medicare-covered.
  • VERIS™

Products and services

  • VERIS™ VERIS is a daily wound dressing combining collagen and Mānuka honey for routine use in clinic settings. It is FDA-cleared, reimbursed by Medicare and most commercial plans as a low-cost wound supply (HCPCS A6021, collagen), and designed for healthcare providers treating common wounds seen every day in clinic.
  • APIS® APIS is a weekly cellular tissue product (CTP) / skin substitute combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite for the treatment of chronic and acute wounds. It is FDA-cleared, non-human (no placental, umbilical, or other human tissue), Medicare-covered under HCPCS A2010, and available across MACs and in Veterans Affairs and Department of Defense facilities.

Quantifiable outcome

  • 100% wound closure within 8 weeks (mean 4.1 weeks) in 12-patient chronic wound case series
  • +4 more outcomes

Companies that use SweetBio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

SweetBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SweetBio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BioLab HoldingscoreChannel Partner/ Reseller/ Distributor · 27 April 2026Strategic distribution partnership to expand access to SweetBio's APIS bioengineered wound care products through BioLab's national distribution network. Expected to accelerate adoption among clinicians across care settings while strengthening BioLab's continuum-of-care portfolio.
  • Resolve MedicalcoreChannel Partner/ Reseller/ Distributor · 25 March 2026Commercial launch partnership for APIS through Resolve Medical's established network of healthcare providers across the United States. Resolve Medical leads product distribution and launch activities.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

SweetBio competitors and assessment

Company assessment

Emerging players

  • Resolve Medical: Specialty distributor focused on bringing advanced wound care products to US healthcare providers; leads APIS® commercial launch. Comparable as a channel peer and emerging commercialization partner in the advanced wound care category.
  • BioLab Holdings: Wound care distributor that recently added SweetBio's APIS® to its national portfolio. Comparable as a strategic channel peer whose continuum-of-care portfolio increasingly competes with and complements bioengineered skin substitute offerings.

Broad incumbents

  • ConvaTec Group: Major advanced wound care incumbent offering foam, hydrocolloid, antimicrobial, and biologic wound dressings. Overlaps with SweetBio on collagen and antimicrobial wound dressings (similar HCPCS A-codes) but operates at significantly broader global scale.
  • Medline Industries: Largest privately-held manufacturer and distributor of medical supplies, including a broad wound care portfolio. Comparable as both a competing supplier and a channel partner option for SweetBio's hospital and clinic customers.
  • 3M Health Care (KCI): Owns the KCI negative pressure wound therapy franchise plus a range of advanced wound dressings. Comparable as a large channel competitor in advanced wound care, especially for hospital systems where SweetBio sells through BioLab and Resolve Medical.
  • Smith & Nephew: Global medical device incumbent with a large Advanced Wound Management portfolio (collagen dressings, honey-based dressings, skin substitutes via the Osiris acquisition). Comparable in product overlap (collagen/honey wound dressings, CTP/skin substitutes) though operating at much greater scale across multiple categories.
  • Coloplast: Global wound and skin care company with extensive advanced wound dressings portfolio. Overlaps with SweetBio on collagen-based and antimicrobial wound dressings sold into similar healthcare provider and outpatient settings.
  • Integra LifeSciences: Diversified regenerative medicine company with skin substitutes (e.g., Integra Dermal Regeneration Template) and wound care products. Comparable on regenerative skin substitute technology and Medicare-reimbursed wound care sales channels.

Direct peers

  • MiMedx Group: Develops and markets placental tissue allografts used as skin substitutes and wound coverings. Directly comparable to SweetBio in product category (skin substitute/CCTPs), reimbursement dynamics under HCPCS Q-codes/A-codes, and target customer (wound care clinics, dermatologists, VA/DOD).
  • Organogenesis Holdings: A leading regenerative medicine company commercializing skin substitutes and wound care biologics (e.g., Apligraf, Dermagraft). Directly comparable to SweetBio as both sell FDA-cleared, Medicare-covered skin substitutes/CTPs into the chronic and acute wound care market under similar HCPCS reimbursement pathways.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SweetBio social profiles

Digital presence

SweetBio compliance and trust

Trust signal

Compliance1 record

SweetBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SweetBio leadership team

Management profile

Number of profiles

Profiles3 records

SweetBio funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SweetBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SweetBio

What does SweetBio do?

SweetBio develops and sells FDA-cleared, Medicare-covered bioengineered wound care dressings built on a proprietary combination of UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite. The company sells two SKUs — VERIS, a daily collagen dressing reimbursed under HCPCS A6021, and APIS, a weekly cellular tissue product/skin substitute reimbursed under HCPCS A2010 — to wound care clinics, dermatology departments, and hospital systems through national distribution partners.

Is SweetBio a public or private company?

SweetBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was SweetBio founded?

SweetBio was founded in 2015. It employs 11 to 50 people.

Where is SweetBio based?

SweetBio is headquartered in Memphis, United States, in the North America region.

How does SweetBio make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are distribution Partnership Revenue.

Who are SweetBio's main competitors?

Emerging players on record are Resolve Medical and BioLab Holdings. Broad incumbents are ConvaTec Group, Medline Industries, 3M Health Care (KCI), Smith & Nephew, Coloplast and Integra LifeSciences. Direct peers are MiMedx Group and Organogenesis Holdings.

Does SweetBio have an API?

No public API is recorded for SweetBio.

What industry is SweetBio in?

SweetBio's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireHARTMANN USA Expands Advanced Wound Care Portfolio Through Exclusive Distribution Agreement with SweetBio®HARTMANN USA announced an exclusive national distribution agreement with SweetBio for VERIS™, a wound care product combining collagen and Mānuka honey. The deal expands clinician access across the U.S., with distribution starting November 1, 2026.PR NewswireBioLab Holdings Announces Strategic Partnership with SweetBio® to Expand Continuum of Wound Care SolutionsBioLab Holdings, Inc. announced a strategic distribution partnership with SweetBio, Inc. to expand access to SweetBio's APIS® bioengineered wound care products through BioLab's national distribution network. The APIS® product is the first and only wound care solution combining UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite for treatment of chronic and acute wounds. The collaboration is expected to accelerate adoption among clinicians across care settings while strengthening BioLab's continuum-of-care portfolio, with SweetBio's products already Medicare-covered and FDA-cleared.Memphis LocalSweetBio rolls out new, longer-lasting wound productSweetBio has recently launched Apis, a new wound-care patch designed for treating more serious wounds. The company, established over a decade ago, uses manuka honey and collagen to create accessible wound care solutions and currently delivers hundreds of thousands of patches annually across the U.S. The product aims to enhance the effectiveness of wound treatment for patients and healthcare providers.EIN PresswireSWEETBIO BRINGS APIS® BIOENGINEERED WOUND PRODUCT TO MARKET THROUGH PARTNERSHIP WITH RESOLVE MEDICALSweetBio announced the commercial launch of APIS, its second bioengineered wound care product, through a strategic distribution partnership with Resolve Medical. APIS is the first wound care product to combine UMF-certified Mānuka honey, collagen derivative, and hydroxyapatite, and is non-human, containing no placental, umbilical, or other human tissue. Resolve Medical will serve as the distribution partner, leading the product launch through its established network of healthcare providers across the United States.American City Business JournalsSweetBio founder turned family tragedy into biotech startup that makes wound care affordableAfter years of challenges with investors and regulators, the founder of SweetBio established a biotech startup to provide affordable wound care solutions. The company has developed an FDA-cleared product that is covered by Medicare. This initiative highlights the intersection of personal tragedy and entrepreneurial innovation in the healthcare sector.American City Business JournalsSweetBio founder turned family tragedy into biotech startup that makes wound care affordableSweetBio was founded in 2015 by Kayla Rodriguez Graff and her brother Isaac, who developed a collagen and Manuka honey technology for wound care. The company recently launched VERIS™, an FDA-cleared, Medicare-covered wound care solution that offers effective recovery at a significantly reduced cost compared to traditional alternatives. This innovation aims to improve access to high-quality wound care, reflecting the founders' commitment to addressing real health challenges.American City Business JournalsMemphis Inno Startups to Watch: SweetBioSweetBio has been named to the Memphis Inno Startups to Watch list, highlighting its work in developing Apis products. The startup is partnering with MiroDX to distribute these healthcare solutions via comprehensive patient kits.American City Business JournalsSweetBio gears up for commercial launch, looks to get product into homesSweetBio is preparing for the commercial launch of its bioengineered wound care product, Apis, scheduled for early in the fourth quarter. The company has secured Medicare reimbursement and aims to expand distribution beyond hospitals into home care settings. To support this growth and larger Series A funding, SweetBio is currently raising a $500,000 seed round.HOLAKayla Rodriguez GraffSweetBio, a Memphis-based medical device company founded by Kayla and Isaac Rodriguez, has secured $4 million in funding from VamosVentures to support its advanced wound care products derived from Manuka honey. The company's FDA-cleared devices target diabetic ulcers, focusing on communities of color disproportionately affected by diabetes. This investment enables SweetBio to expand its national commercial success and further develop its strategy for market growth.The Mac ObserverBiotech Startup ‘SweetBio’, VC Firm “VamosVentures, Get Funded by AppleApple’s Racial Equity and Justice Initiative has funded a biotech startup called SweetBio and venture capital firm VamosVentures. The funding, totaling US$50 million, aims to support diverse, technology-enabled companies, particularly those owned by Black and Latinx individuals. SweetBio, co-founded by siblings Kayla and Isaac Rodriguez, focuses on advanced wound care utilizing honey-based solutions.